Prof. Xinjing Tang and Dr. Qian Wang developed a miRNA-based PROTACs strategy to target the degradation of Lin28 protein for the combined breast cancer therapy
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center. Prof. Xinjing Tang and Dr. Qian Wang developed a miRNA-based PROTACs strategy to target the degradation of Lin28 protein for the combined breast cancer therapy[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(9): 875-876.
>
>